@article{fdi:010085876,
  title = {{I}n vitro activity of therapeutic antibodies against {SARS}-{C}o{V}-2 {O}micron {BA}.1, {BA}.2 and {BA}.5},
  author = {{T}ouret, {F}. and {B}aronti, {C}{\'e}cile and {P}astorino, {B}. and {V}illarroel, {P}. {M}. {S}. and {N}inove, {L}. and {N}ougairede, {A}. and {L}amballerie de, {X}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he replacement of the {O}micron {BA}.1 variant of {SARS}-{C}o{V}-2 by the {BA}.2 and the rapid growth of the {BA}.5 sub lineage, which have both different sets of mutations in the spike glycoprotein, alters the spectrum of activity of therapeutic antibodies currently licensed in the {E}uropean {U}nion. {U}sing clinical strains of the {O}micron {BA}.2 and {BA}.5 variants, we compared the neutralising power of monoclonal antibodies against the {O}micron {BA}.1, {BA}.2 and {BA}.5 variants, using an ancestral strain (lineage {B}.1, {D}614{G}) and a {D}elta variant strain as reference. {S}otrovimab/{V}ir-7831 is less active against {BA}.2 than against {BA}.1 (fold change reduction similar to 1,4) and even less active against {BA}.5 (fold change reduction similar to 2.7). {W}ithin the {E}vusheld /{AZD}7442 cocktail, {C}ilgavimab/{AZD}1061 is more active against {BA}.2 and {BA}.5 than against {BA}.1 (fold change increase similar to 32), whilst the very low activity of {T}ixagevimab/{AZD}8895 against {BA}.1 is not enhanced against {BA}.2 nor {BA}.5. {I}n total, compared to {BA}.1, the activity of the {E}vusheld/{AZD}7442 is significantly improved against {BA}.2 while {BA}.5 is intermediate but closer to {BA}.2.},
  keywords = {},
  booktitle = {},
  journal = {{S}cientific {R}eports - {N}ature},
  volume = {12},
  numero = {1},
  pages = {12609 [6 p.]},
  ISSN = {2045-2322},
  year = {2022},
  DOI = {10.1038/s41598-022-16964-z},
  URL = {https://www.documentation.ird.fr/hor/fdi:010085876},
}